Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) — Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev Redkar, Ph.D., President of Apollomics, will present virtually at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024 at 10:40 a.m. ET.
Related news for (APLM)
- Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
- 24/7 Market News Snapshot 31 March, 2025 – Apollomics Inc. Class A Ordinary Shares (NASDAQ:APLM)
- Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
- Apollomics and LaunXP Team Up to Supercharge Vebreltinib in Asia’s NSCLC Fight
- Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia